The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Open accessAbstract
BACKGROUND: Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable. METHODS: We conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per day) with monthly intravenous cyclophosphamide (0.5 g per square meter of body-surface area, increased to 1.0 g per square meter) as induction therapy for active lupus nephritis. A change to the alternative regimen was allowed at 12 weeks in patients who did not have an early response. The study protocol specified adjunctive care and the use and tapering of corticosteroids. The primary end point was complete remission at 24 weeks (normalization of abnormal renal measurements and maintenance of baseline normal measurements). A secondary end point was partial remission at 24 weeks. RESULTS: Of 140 patients recruited, 71 were randomly assigned to receive mycophenolate mofetil and 69 were randomly assigned to receive cyclophosphamide. At 12 weeks, 56 patients receiving mycophenolate mofetil and 42 receiving cyclophosphamide had satisfactory early responses. In the intention-to-treat analysis, 16 of the 71 patients (22.5 percent) receiving mycophenolate mofetil and 4 of the 69 patients receiving cyclophosphamide (5.8 percent) had complete remission, for an absolute difference of 16.7 percentage points (95 percent confidence interval, 5.6 to 27.9 percentage points; P=0.005), meeting the prespecified criteria for noninferiority and demonstrating the superiority of mycophenolate mofetil to cyclophosphamide. Partial remission occurred in 21 of the 71 patients (29.6 percent) and 17 of the 69 patients (24.6 percent), respectively (P=0.51). Three patients assigned to cyclophosphamide died, two during protocol therapy. Fewer severe infections and hospitalizations but more diarrhea occurred among those receiving mycophenolate. CONCLUSIONS: In this 24-week trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
(2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440513 · Cited by 539
Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., & Li, F.-K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080686 · Cited by 479
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20666 · Cited by 391
Factors predictive of outcome in severe lupus nephritis
Korbet, S. M., Lewis, E. J., Schwartz, M. M., Reichlin, M., Evans, J., & Rohde, R. D. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70262-9 · Cited by 374
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citationBertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070367 · Cited by 762
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Self-citationManagement strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Self-citationThe frequency and outcome of lupus nephritis: results from an international inception cohort study
Hanly, J. G., O’Keeffe, A. G., Su, L., Urowitz, M. B., Romero-Diaz, J., Gordon, C., Bae, S.-C., Bernatsky, S., Clarke, A. E., Wallace, D. J., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kev311 · Cited by 647
Self-citationMycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Self-citationHoussiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Cauli, A., Direskeneli, H., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.102533 · Cited by 542
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Houssiau, F. A., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., Fiehn, C., de Ramon Garrido, E., Gilboe, I.-M., Tektonidou, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131995 · Cited by 499
Condon, M. B., Ashby, D., Pepper, R. J., Cook, H. T., Levy, J. B., Griffith, M., Cairns, T. D., & Lightstone, L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202844 · Cited by 454
Glutathione peroxidase 4–regulated neutrophil ferroptosis induces systemic autoimmunity
Li, P., Jiang, M., Li, K., Li, H., Zhou, Y., Xiao, X., Xu, Y., Krishfield, S., Lipsky, P. E., Tsokos, G. C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00993-3 · Cited by 446
Hoi, A., Igel, T., Mok, C. C., & Arnaud, L. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00398-2 · Cited by 399
Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1030 · Cited by 396
Merrill, J. T., Burgos‐Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J. ‐., Kelly, S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27601 · Cited by 376
Self-citationSystemic Lupus Erythematosus in Children and Adolescents
Levy, D. M., & Kamphuis, S. (2012) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2012.03.007 · Cited by 359
Immune and Inflammatory Role in Renal Disease
Imig, J. D., & Ryan, M. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120028 · Cited by 356
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Isenberg, D., Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Jayne, D., Sánchez-Guerrero, J., Wofsy, D., Yu, X., & Solomons, N. (2010) · Rheumatology · doi:10.1093/rheumatology/kep346 · Cited by 356
Self-citationMysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., Houssiau, F. A., Drappa, J., Close, D., Maciuca, R., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38037 · Cited by 353
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos‐Vargas, R., Chen, S., Hillson, J. L., Meadows‐Shropshire, S., Kinaszczuk, M., & Merrill, J. T. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38260 · Cited by 341
Self-citationRedefining lupus nephritis: clinical implications of pathophysiologic subtypes
Yu, F., Haas, M., Glassock, R., & Zhao, M.-H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.85 · Cited by 340
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring
Hsieh, C., Chang, A., Brandt, D., Guttikonda, R., Utset, T. O., & Clark, M. R. (2011) · Arthritis Care & Research · doi:10.1002/acr.20441 · Cited by 321
Value of a Complete or Partial Remission in Severe Lupus Nephritis
Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M., & Lewis, E. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03280807 · Cited by 312
Levey, A. S., Cattran, D., Friedman, A., Miller, W. G., Sedor, J., Tuttle, K., Kasiske, B., & Hostetter, T. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.04.029 · Cited by 298
The ACCESS Trial Group (2014) · Arthritis & Rheumatology · doi:10.1002/art.38790 · Cited by 288
Ginzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3738 · Cited by 284
Self-citationSystemic lupus erythematosus diagnosis and management
Thong, B., & Olsen, N. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kew401 · Cited by 120
High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus
Parker, B., & Bruce, I. (2007) · Lupus · doi:10.1177/0961203307079502 · Cited by 80
Pego‐Reigosa, J. M., Cobo‐Ibáñez, T., Calvo‐Alén, J., Loza‐Santamaría, E., Rahman, A., Muñoz‐Fernández, S., & Rúa‐Figueroa, Í. (2013) · Arthritis Care & Research · doi:10.1002/acr.22035 · Cited by 74
Metadata
- Authors
- Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., & Appel, G. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2219-2228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160388191
- Cited by
- 1,128
- References
- 22
- FWCI
- 40.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.